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MEG3 long noncoding RNA regulates the TGF-b
pathway genes through formation of RNA–DNA
triplex structures
Tanmoy Mondal1, Santhilal Subhash1, Roshan Vaid1, Stefan Enroth2, Sireesha Uday1, Bjo¨rn Reinius1,
Sanhita Mitra1, Arif Mohammed1, Alva Rani James1, Emily Hoberg3, Aristidis Moustakas4,5,
Ulf Gyllensten2, Steven J.M. Jones6, Claes M. Gustafsson3, Andrew H. Sims7, Fredrik Westerlund8,
Eduardo Gorab9 & Chandrasekhar Kanduri1
Long noncoding RNAs (lncRNAs) regulate gene expression by association with chromatin,
but how they target chromatin remains poorly understood. We have used chromatin RNA
immunoprecipitation-coupled high-throughput sequencing to identify 276 lncRNAs enriched
in repressive chromatin from breast cancer cells. Using one of the chromatin-interacting
lncRNAs, MEG3, we explore the mechanisms by which lncRNAs target chromatin. Here we
show that MEG3 and EZH2 share common target genes, including the TGF-b pathway genes.
Genome-wide mapping of MEG3 binding sites reveals that MEG3 modulates the activity of
TGF-b genes by binding to distal regulatory elements. MEG3 binding sites have GA-rich
sequences, which guide MEG3 to the chromatin through RNA–DNA triplex formation. We
have found that RNA–DNA triplex structures are widespread and are present over the MEG3
binding sites associated with the TGF-b pathway genes. Our ﬁndings suggest that RNA–DNA
triplex formation could be a general characteristic of target gene recognition by the
chromatin-interacting lncRNAs.
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L
ong noncoding RNAs (lncRNAs) have emerged as key
regulators of important biological processes implicated in
development and differentiation1–6. Studies on the mode of
action of lncRNAs have revealed that a subset of lncRNAs regulate
gene expression in cis and trans by interacting with chromatin and
recruiting chromatin modiﬁers7–12. Most studies to date have
focused on identiﬁcation of the RNA-interacting protein partners
involved in gene activation or gene silencing13–16, and less
attention has been paid in understanding how lncRNAs
speciﬁcally target genes. Nevertheless, some recent investigations
have provided insights into Xist targeting and its spreading
along the inactive X chromosome (Xi)17,18. These studies did not
predict any consensus binding sites by which Xist RNA is
initially recruited before spreading along the Xi, but it has been
proposed that the three-dimensional chromosomal conformation
may play an important role in Xist spreading. On the other
hand, chromatin-binding maps of HOTAIR and Drosophila roX2
lncRNAs revealed that GA-rich sequences are the preferred
binding motif, indicating that GA-rich sequences may help
these RNAs to target the chromatin19. Identiﬁcation of the
lncRNAs that are associated with chromatin and exploration of
the mechanistic aspects of the chromatin targeting of lncRNAs
will help us to understand the molecular intricacies under-
lying lncRNA-dependent gene expression at the transcriptional
level.
Active and inactive epigenetic modiﬁcations of the chromatin
can regulate gene expression at the transcriptional level. When
chromatin is enriched with repressive histone marks such as
H3K27me3 and H3K9me3, it negatively regulates transcription20.
The H3K27me3 histone modiﬁcation is mediated by polycomb
repressive complex 2 (PRC2). EZH2, EED and SUZ12 are the
three major components of the PRC2 complex, where EZH2
is the catalytic subunit and EED is known to help in the
propagation of H3K27me3 marks by allosteric activation of PRC2
(refs 21,22). In Drosophila, the recruitment of PRC2 to the
chromatin is mediated by speciﬁc sequences known as polycomb
response elements. However, in mammals, it is not clear how
sequence-speciﬁc recruitment of the PRC2 occurs across the
genome. Recent evidence of a strong association between lncRNA
and the PRC2 complex raise the possibility that lncRNAs may act
as guiding molecules for PRC2 to target the chromatin23.
Several previous studies have focused on the identiﬁcation of
the polycomb-interacting lncRNAs either by using the RNA
immunoprecipitation (RIP) technique or the photoactivatable
ribonucleside-enhanced crosslinking and immunoprecipitation
technique24–27. Although these studies have identiﬁed several
PRC2-interacting lncRNAs, it remains unclear whether these
lncRNAs are targeted to the chromatin.
Hence we sought to identify the repressive chromatin-
associated lncRNAs on a global scale and also characterize
the mechanisms by which these lncRNAs are targeted to the
chromatin. Here we have characterized the repressive chromatin-
associated lncRNAs on a genome-wide scale by performing
chromatin RIP followed by high-throughput sequencing
(ChRIP-seq) using antibodies to H3K27me3 and EZH2 in
BT-549 cells. We identiﬁed 276 lncRNAs that are enriched in
repressive chromatin. By using one of the chromatin-interacting
lncRNAs (MEG3) as a model system, we explored the
mechanisms by which it recognizes target genes. Consistent with
ChRIP-seq data, MEG3 interacts with the PRC2 complex.
Through loss-of-function experiments of MEG3 and EZH2, we
found that MEG3 in cooperation with PRC2 regulates a common
set of genes, including those of the transforming growth factor-b
(TGF-b) pathway. Using a modiﬁed chromatin oligo afﬁnity
precipitation (ChOP) method, we ﬁne-mapped genome-wide
chromatin-binding sites for MEG3 RNA, revealing some of the
TGF-b pathway genes as direct targets. MEG3 binding sites
showed enrichment in GA-rich sequences and we found that
these GA-rich sequences guide MEG3 RNA to its target genes
through formation of RNA–DNA triplex structures. Our data
demonstrate that RNA–DNA triplex structures are widespread
in vivo, and are also present in the vicinity of the TGF-b pathway
genes. Taken together, these results suggest that RNA–DNA
triplex formation may be a general mechanism for target gene
recognition by lncRNAs.
Results
Characterization of repressive chromatin-enriched lncRNAs.
Previously, we have used ChRIP to verify the chromatin
association of the mouse Kcnq1ot1 antisense lncRNA10. Here we
used a modiﬁed ChRIP protocol in combination with photo-
activatable ribonucleside-enhanced crosslinking followed by
high-throughput sequencing (ChRIP-seq) to identify lncRNAs
that are associated with repressive chromatin on a global
scale (Fig. 1a). In brief, we incubated BT-549 cells overnight
(14–16 h) with 4-thiouridine (4sU), followed by a 40-min
incubation with actinomycin D (ActD). ActD-treated BT-549
cells were crosslinked with formaldehyde, followed by ultraviolet
irradiation. 4sU-incorporated RNA can be crosslinked with
proteins in vivo by ultraviolet irradiation. Crosslinking with
formaldehyde ensures stabilization of the chromatin-interacting
Figure 1 | Identiﬁcation of repressive chromatin-associated lncRNAs using ChRIP-seq. (a) The ChRIP-seq analysis pipeline used to identify lncRNAs
enriched in repressive chromatin. The pie chart shows 276 lncRNAs enriched in both EZH2 and H3K27me3 ChRIP-seq samples compared with the nuclear
RNA (input). The P value was obtained by performing a hypergeometric test using all the lncRNAs in our analysis. (b) Bar diagram showing the distribution
of T-to-C transitions (indicative of putative RNA–protein contact sites) in input (8,361), EZH2 (18,905) and H3K27me3 (2,651) ChRIP-seq data. Black in the
EZH2 bar indicates the number of T-to-C transitions (1,253) that are either present in input or H3K27me3 samples, and blue indicates EZH2-speciﬁc T-to-C
transitions (17,652). The EZH2-speciﬁc T-to-C transitions (17,652) were used to associate with lncRNAs. (c) All the possible conversions present in the
EZH2 ChRIP-seq sample. T-to-C conversion and the reverse-strand A-to-G conversions were predominant among all the possible conversion events.
(d) LncRNAs (1,046; annotated and non-annotated) harbour EZH2-speciﬁc (17,652) T-to-C conversion site. Seventy repressive chromatin-enriched
lncRNAs (out of 276) carry T-to-C transitions, including known PRC2-interacting lncRNAs such as MEG3, KCNQ1OT1 and BDNF-AS1. The P value was
obtained by performing a hypergeometric test using all the lncRNAs considered in our analysis. (e,f) The distribution of the sequencing reads on MEG3 and
KCNQ1OT1 transcripts from H3K27me3, EZH2-enriched chromatin fractions and input RNA samples. The tags represent the read distribution and the signal
represents the intensity of reads over MEG3 and KCNQ1OT1 transcripts. Locations of T-to-C transitions over the exons are depicted below the physical
maps. The left panel depicts the RPKM (Reads per kilobase per million) for MEG3 and KCNQ1OT1 in H3K27me3, EZH2 ChRIP RNA and input RNA samples.
The fold enrichment (FC) in H3K27me3 and EZH2 ChRIP RNA compared with input is indicated. (g) ChRIP validation: RT–qPCR data showing the
enrichment of the selected annotated and non-annotated lncRNAs in the EZH2 and H3K27me3 ChRIP pull-downs compared with input. We did not observe
any enrichment of these lncRNAs in the H3K4me2 (active chromatin marks) and immunoglobulin G (IgG; nonspeciﬁc antibody) ChRIP pull-downs. Actin
was used as a negative control. Data represent the mean±s.d. of three independent biological experiments.
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lncRNAs to the chromatin. Incubation of BT-549 cells with ActD
before crosslinking blocks transcription, which in turn prevents
the co-transcriptional crosslinking of lncRNAs to the chromatin.
The efﬁcacy of the transcriptional arrest by ActD was tested
using short half-life mRNA C-MYC as described previously
(Supplementary Fig. 1a)28. Chromatin was prepared from the
formaldehyde and ultraviolet -crosslinked BT-549 cells, and was
subjected to immunoprecipitation using antibodies to H3K27me3
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and EZH2. The speciﬁcity of the immunopuriﬁed chromatin was
tested by quantitative PCR (qPCR) with positive and negative
controls (Supplementary Fig. 1b). After reversal of crosslinking,
RNA was isolated from the immunoprecipitated chromatin.
Isolated RNA was extensively treated with DNase I to remove all
traces of DNA, and veriﬁed again by qPCR (Supplementary
Fig. 1b). The DNase I-treated anti-H3K27me3 and anti-EZH2
puriﬁed RNAs along with nuclear input RNA were subjected to
high-throughput sequencing. The reconstruction of the nuclear
RNA using Cufﬂinks revealed previously annotated lncRNAs
and also non-annotated transcripts. Coding potential analysis
of the non-annotated transcripts found that they had lower
coding probabilities, suggesting that they are noncoding RNAs
(Supplementary Fig. 1c). We looked for enrichment of the
annotated and non-annotated transcripts in H3K27me3 and
EZH2 ChRIP-puriﬁed RNA fractions over nuclear input
(Supplementary Data 1 and 2). We considered lncRNAs in our
ChRIP data set to be ‘repressive chromatin enriched’ only
if they were enriched (minimum twofold) in both H3K27me3
and EZH2 ChRIP-puriﬁed RNA fractions compared with the
nuclear input. We found a signiﬁcant overlap (276 lncRNAs,
Po9.9e 52, hypergeometric distribution) between H3K27me3
and EZH2 ChRIP pull-downs (Fig. 1a). The list of 276 lncRNAs
enriched in repressive chromatin comprises both annotated
and non-annotated transcripts (Supplementary Data 3). The 4sU
incorporation provided us with an additional advantage in our
RNA sequencing data, as the possible protein interaction sites on
RNA lead to ultraviolet-induced T-to-C transitions. The T-to-C
conversions at the putative RNA–protein contact sites in ChRIP
RNA sequencing samples were considered only if the minimum
sequencing read depth over the conversions was Z2 (read depth
indicates total number of sequencing reads covered per
transition)29. Using this criterion, we observed that T-to-C
conversion was overrepresented in the EZH2 ChRIP RNA
fraction in comparison with both the H3K27me3 ChRIP RNA
and input RNA (Fig. 1b). We found that the overrepresentation
of T-to-C conversion in EZH2 ChRIP data was not by chance, as
the other nucleotide conversions were detected at background
level in the EZH2 ChRIP data compared with T to C (A to G
also represents T-to-C conversion in the reverse strand of
RNA sequencing data; Fig. 1c). We identiﬁed 17,652 T-to-C
conversions that were present only in EZH2 ChRIP data but not
in H3K27me3 and input RNA data. These T-to-C conversions
were then mapped to annotated and non-annotated transcripts,
reconstructed from nuclear RNA input, revealing 1,046 lncRNAs
with putative RNA–protein contact sites. We found a signiﬁcant
overlap between these lncRNAs and the lncRNAs that were
enriched in EZH2 ChRIP and in repressive chromatin (enriched
in both H3K27me3 and EZH2 ChRIPs) (Fig. 1d, Supplementary
Fig. 1d and Supplementary Data 4). The presence of EZH2
ChRIP-speciﬁc T-to-C conversion sites over the repressive
chromatin-associated lncRNAs indicates that they are either
putative EZH2 contact sites or EZH2-associated protein
contact sites over the lncRNAs. Interestingly, the 70 repressive
chromatin-associated lncRNAs with T-to-C conversions contain
several annotated and non-annotated (both intergenic and
intronic) lncRNAs (Supplementary Data 4 and Supplementary
Fig. 2a,b), including three known PRC2-interacting lncRNAs:
KCNQ1OT1, MEG3 and BDNF-AS1 (Fig. 1e,f and Supplementary
Data 4). Mouse orthologues Kcnq1ot1 and Gtl2 have been
shown to interact with PRC2, and moreover Kcnq1ot1 has
also been shown to be enriched in the mouse placental chromatin
fraction10,24,30. We validated the repressive chromatin enrich-
ment of some of the annotated lncRNAs (BDNF-AS1, MEG3,
KCNQ1OT1 and LINC00422) and non-annotated lncRNAs
(intergenic CUFF.16286 and intronic CUFF.9557) using qPCR
assay on ActD-treated and -untreated ChRIP materials (Fig. 1g
and Supplementary Fig. 2c).
Mapping PRC2-interacting region of MEG3 lncRNA. Since
MEG3 lncRNA was identiﬁed as a repressive chromatin-asso-
ciated RNA in the ChRIP analysis (Fig. 1d,e), and also as
one of the chromatin-interacting RNAs in our previous study
involving sucrose-fractionated chromatin from normal human
ﬁbroblasts (HF cells)28, we were interested in exploring plausible
mechanisms by which MEG3 lncRNA recognizes its target genes.
HumanMEG3 is an lncRNA ofB1,700 nucleotides with different
isoforms generated by alternative splicing. Exons 1–3 and 8–9 are
common to all isoforms, whereas exons 4–7 are present in
different combinations31. In situ RNA hybridization and nuclear–
cytoplasmic RNA fractionation experiments indicated that MEG3
is located in the nuclear compartment (Fig. 2a,b). We checked for
the interaction of MEG3 lncRNA with PRC2 by RIP and found
robust enrichment of MEG3 in the PRC2-interacting RNA
fraction (Fig. 2c), and its fold enrichment was more or less similar
to the enrichment of KCNQ1OT1 lncRNA (Fig. 2c), which was
used as positive control for the RIP experiment.
We then wanted to ﬁne-map the sequences ofMEG3 RNA that
dictate interaction of PRC2 with MEG3. To this end, we looked
for the status of the incorporated 4sU nucleotide conversions
(T to C) in the EZH2 ChRIP-seq data, which indicates possible
RNA–protein contact points. We detected two converted
nucleotides at the 50-end of the MEG3 RNA in the EZH2
Figure 2 | Molecular characterization of MEG3 and PRC2 interaction. (a) RNA-ﬂuorescence in situ hybridization showing the distribution of the MEG3
signal (green) in the nucleus (blue, stained with 4,6-diamidino-2-phenylindole). An RNase A-treated sample was used as a negative control. Scale bar,
1mm. (b) RT–qPCR data showing the distribution of lncRNAs and protein-coding RNAs in the nuclear and cytoplasmic fractions (±s.d., n¼ 3). (c) RT–qPCR
analysis of MEG3, KCNQ1OT1 and U1SnRNA in EZH2 RIP-puriﬁed RNA from BT-549 cells. U1SnRNA served as negative control. The enrichment is plotted as
percentage of input (±s.d., n¼ 3). (d) Physical map of the MEG3 containing numbered exons showing two T-to-C transitions. The exons in red are
constitutively expressed and blue are alternatively spliced exons. First conversion is part of exon 3 showing higher expression, whereas the second
conversion is part of exon 4 showing low expression in the nuclear RNA sequencing. (e) In vitro interaction ofMEG3 and PRC2. The schematic indicates the
exons of the WT MEG3 clone. Left: RT–qPCR showing enrichment of sense WT MEG3 and MEG3 carrying deletions (D340-348 or D345-348 MEG3) in
in vitro RNA binding assays. Reaction with antisense WT MEG3 or without puriﬁed PRC2 served as negative controls. The binding efﬁciency of MEG3
deletions were presented relative to WT MEG3 (±s.d., n¼ 3). Right: RT–qPCR showing the quantiﬁcation of input RNAs. (f) Upper panel: western blot
showing EZH2 levels after pull-down with biotinylated sense WT MEG3, antisense WT MEG3, and D345-348 MEG3 RNAs incubated with nuclear extract.
This is a representative data set from several experiments. Lower panel: agarose gel picture showing input biotin-RNA. (g) RT–qPCR result showing the
relative enrichment of WT MEG3, D340-348 and D345-348 MEG3 RNAs in the EZH2-RIP, performed after BT-549 cells were transfected with WT and
mutant MEG3 plasmids. Data were normalized to the input RNAs and plotted as percentage of input (±s.d., n¼ 3). To distinguish the endogenous MEG3
from the ectopically expressed MEG3, we designed RT–qPCRs primers, with one primer mapped to the transcribed portion of the vector and the other to
MEG3 RNA. Endogenous MEG3 served as positive control and U1SnRNA as negative control.
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immunopuriﬁed RNA (Figs 1e and 2d), indicating that the
conversions could be possible contact points for EZH2 or EZH2-
associated protein contact sites. The ﬁrst conversion was located
in a constitutively expressed exon 3, whereas the second one was
in an alternatively spliced exon 4 (ref. 31). We PCR-ampliﬁed
full-length MEG3 clones using nuclear RNA from BT-549 cells
(hereon referred to as wild-type (WT) MEG3). It contains all the
constitutively expressed exons (that is, exons 1–3 and 8–9) and an
alternatively spliced exon 7 (out of the four alternatively spliced
exons 4–7), but not exon 4. Moreover, we detected fewer reads in
the nuclear RNA over the alternatively spliced exon with the
second T-to-C conversion (Fig. 2d). Since we failed to detect the
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alternatively spliced exon 4 in several full-length ampliﬁed MEG3
clones, we therefore focused on the ﬁrst T-to-C conversion
located in the constitutively expressed exon 3. We inserted two
deletions of 4 bp (345–348) and 9 bp (340–348) (Fig. 2e),
overlapping the ﬁrst conversion site in exon 3, into a WT
MEG3 clone. We carried out an in vitro binding assay with WT
and mutant (D340-348 MEG3 and D345-348 MEG3) MEG3
RNAs using puriﬁed PRC2 complex, comprising EZH2, EED
and SUZ12 subunits (Fig. 2e and Supplementary Fig. 3a). An
antisense version of the full-length MEG3 (antisense WT MEG3)
was used as a negative control. We found that the PRC2 binding
was partially compromised in the mutant MEG3 RNAs
(D340-348 MEG3 and D345-348 MEG3) compared with the
WT MEG3 (Fig. 2e). We also tested the binding of WT and
D345-348 MEG3 RNAs with PRC2 using the nuclear lysate from
BT-549 cells, and found that the sense WT MEG3, but not the
D345-348 MEG3 RNA, efﬁciently bound to PRC2, as detected by
EZH2 immunoblot (Fig. 2f). To further test the efﬁcacy of the
association of PRC2 with the WT and mutant MEG3 RNAs
in vivo, we transfected BT-549 cells with the plasmids expressing
WT, D340-348 and D345-348 MEG3 RNAs, and performed
RIP. By using primer combinations that selectively amplify
the transfected plasmid-derived MEG3 RNAs, we found that
D340-348 MEG3 and D345-348 MEG3 transcripts were less
enriched than the WT-transfected MEG3, whereas endogenous
MEG3 was equally enriched in all pull-downs (Fig. 2g). Thus, by
using 4sU conversion data along with in vitro and in vivo binding
experiments, we had ﬁne-mapped the probable contact points for
PRC2 interaction in the human MEG3 lncRNA.
MEG3/EZH2 interaction regulates the TGF-b pathway genes.
To gain more insights into the functional signiﬁcance of the
interaction of PRC2 with the MEG3 lncRNA, both EZH2 and
MEG3 transcripts were downregulated in BT-549 and HF cells
using small interfering RNA (siRNA), and gene expression pro-
ﬁles were measured using microarray. We observed a signiﬁcant
overlap among the deregulated genes between the EZH2 and
MEG3 data sets from BT-549 and HF cells, indicating a functional
association between the MEG3 lncRNA and EZH2 (Fig. 3a,
Supplementary Data 5 and Supplementary Data 6). MEG3
downregulation did not interfere with EZH2 RNA and protein
levels, and similarly, EZH2 downregulation did not affect MEG3
transcript levels (Fig. 3b,c), suggesting that the overlap observed
between the deregulated genes in the EZH2 and MEG3 data sets
was not due to changes in EZH2 levels upon MEG3 down-
regulation or inMEG3 levels upon EZH2 downregulation. To rule
out off-target effects of the MEG3 siRNA, we used reverse
transcription (RT)–qPCR to validate four target genes upon
MEG3 downregulation using an alternative siRNA against MEG3
(Supplementary Fig. 3b,c).
Pathway analysis of the differentially expressed genes identiﬁed
from microarray revealed that several pathways were affected
in common after MEG3 and EZH2 removal (Table 1 and
Supplementary Data 7). We also performed RNA sequencing of
the MEG3/EZH2 downregulated samples from an independent
biological experiment, and found a signiﬁcant overlap among
differentially expressed genes from the RNA sequencing and
microarray experiments (Supplementary Fig. 4a). Pathway
analysis of the RNA sequencing samples also revealed the same
pathways as those obtained using microarray experiments, further
suggesting a functional interaction between MEG3 and EZH2
(Table 1 and Supplementary Data 7). In addition, similar
pathways were obtained with the commonly deregulated genes
from microarray and RNA sequencing experiments upon MEG3
and EZH2 downregulation (Supplementary Fig. 4b). Since the
TGF-b pathway is one of the well-investigated signalling cascades
in mammals among the affected pathways, we were interested in
understanding the functional role of MEG3 in the regulation of
genes involved in the TGF-b pathway. We validated the
differential expression of the key TGF-b pathway genes TGFB2,
TGFBR1 and SMAD2 in BT-549 and HF cells after siRNA-
mediated downregulation of EZH2 and MEG3 transcripts
(Fig. 3d,e and Supplementary Fig. 4c). The overexpression of
full-length MEG3 and EZH2 resulted in signiﬁcant downregula-
tion of the TGF-b pathway genes TGFB2, TGFBR1 and SMAD2
(Fig. 3f and Supplementary Fig. 4d). Activation of the TGF-b
pathway target genes ACTC1, CNN1 and COL5A1, with
functional roles in cytoskeletal organization, was also observed
upon downregulation of EZH2 and MEG3 by siRNA
(Supplementary Fig. 5a). We further conﬁrmed the TGF-b
pathway-mediated regulation of these genes by treating BT-549
cells with TGF-b2 ligand for 24 h, and, as expected, we observed
activation of expression of the ACTC1, CNN1 and COL5A1 genes
(Supplementary Fig. 5b). We also observed an additive effect on
the activation of these genes if the cells were treated with both
MEG3 siRNA and TGF-b ligand together (Supplementary
Fig. 5c). Activation of these genes was not observed when the
cells were treated with MEG3 siRNA along with a TGF-b
inhibitor (Supplementary Fig. 5c). These results together high-
light how MEG3 regulates its secondary gene targets through
control of the primary TGF-b target genes.
Considering the functional role of the TGF-b pathway in the
regulation of cell invasion32–34, we investigated whether the
activated the TGF-b pathway members in the MEG3-
downregulated cells enhance cell invasion. To this end, we
performed a Matrigel cell invasion assay with the BT-549 cells
transduced with lentiviral particles containing MEG3 and control
short hairpin RNAs (shRNAs). Compared with the control
shRNA, the MEG3 shRNA-transduced BT-549 cells showed
activation of the TGF-b pathway genes (Supplementary Fig. 5d)
and also showed a signiﬁcant increase in their invasion through
Matrigel (Fig. 3g). The increased invasion of the MEG3 shRNA
cells was reversed when the cells were treated with TGF-b
inhibitor (Fig. 3g). We also observed an increase in the cell
invasion of the control shRNA-expressing cells in the presence of
TGF-b2 ligand (Fig. 3g). These results suggest that MEG3 partly
controls the cell invasion of BT-549 cells through regulation of
the TGF-b pathway. When we overexpressed MEG3 in MDA-
MB-231 cells, we found that there was a signiﬁcant decrease in
the invasive capacity of the MDA-MB-231 cells, indicating that
MEG3 RNA suppresses cell invasion (Supplementary Fig. 5e).
Given the functional interaction between MEG3 expression and
TGF-b gene regulation in the breast cancer cell line BT-549, we
extended our cell line analyses to the published clinical breast
cancer data sets. We found that MEG3 is expressed at signiﬁcantly
lower levels in invasive ductal carcinoma than in normal breast
tissue (Supplementary Fig. 5f). We then integrated gene expression
data from 17 published studies, representing 2,999 primary breast
tumours, and found that MEG3 had the lowest average expression
and widest range of expression in the aggressive and difﬁcult-to-
treat basal molecular subtype (Supplementary Fig. 5g). Consistent
with this observation, MEG3 is expressed at lower levels in high-
grade breast tumours (Supplementary Fig. 5h). We also observed
that TGFB2, TGFBR1 and SMAD2 genes (Supplementary Fig. 5i)
had greater expression in tumours with low MEG3 expression,
further supporting our in vitro cell culture results that MEG3
negatively regulates the TGF-b pathway genes (Fig. 3).
MEG3 binds to distal regulatory elements of TGF-b genes. We
next wanted to address an important question: how does MEG3
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Figure 3 | MEG3/EZH2 functional interaction regulates TGF-b pathway genes. (a–c) MEG3 and EZH2 share common gene targets. (a) Venn diagram
showing the number of genes deregulated after downregulation of MEG3 and EZH2 using siRNA in BT-549 and HF cells, and the degree of overlap between
the MEG3- and EZH2-dependent genes. The P values were obtained by hypergeometric test using all protein-coding genes as a background. (b) EZH2
protein levels, as determined by western blotting, following EZH2 and MEG3 downregulation in BT-549 and HF cells. Tubulin was used as a loading control.
(c) RT–qPCR analysis of EZH2 and MEG3 mRNA expression in Ctrlsi, EZH2si and MEG3si transfected BT-549 and HF cells (±s.d., n¼ 3). (d) RT–qPCR
analysis of TGFB2, TGFBR1 and SMAD2 gene expression in Ctrlsi, MEG3si and EZH2si transfected BT-549 cells (±s.d., n¼ 3). (e) Immunoblot showing
SMAD2, TGFBR1 and tubulin protein levels following transfection of BT-549 cells with Ctrlsi and MEG3si. (f) Bar graph showing RT–qPCR analysis of TGFB2,
TGFBR1 and SMAD2 mRNA levels after overexpression of MEG3 (pREP4MEG3) in BT-549 and MDA-MB-231 cells. The levels in pREP4MEG3 are presented
relative to CtrlpREP4 (±s.d., n¼ 3). EZH2 was used as a control showing no change in expression after overexpression of MEG3. The P values were
calculated using Student’s t-test (two-tailed, two-sample unequal variance), *Po0.05. (g) Downregulation of MEG3 inﬂuences the invasive property
of BT-549 cells through regulation of the TGF-b pathway. Images showing Matrigel invasion of the BT-549 cells. The two images in the upper panel show
invasion of BT-549 cells infected with Ctrlsh lentivirus, and Ctrlsh infection followed by incubation with TGF-b2 ligand (Ctrlsh-TGFB2). The images in the
bottom panel show the cells infected with MEG3Sh and MEG3sh infection followed by incubation with TGF-b inhibitor (MEG3shþ TGF-bin). Scale bar, 10
mm. The bar graph shows quantiﬁcation (±s.d., n¼ 3) of the matrix invaded cells in MEG3sh relative to the Ctrlsh. The P values were calculated using
Student’s t-test (two-tailed, two-sample unequal variance), *Po0.05, **Po0.01.
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target the multiple TGF-b pathway genes in trans? For this
purpose, we wanted to ﬁne-map genome-wide MEG3 binding
sites using the ChOP method with minor modiﬁcations. We have
previously used ChOP methodology to characterize the Kcnq1ot1
lncRNA binding sites on mouse chromosome 7 (refs 10,35). This
method is conceptually equivalent to other methods currently
used to ﬁne-map RNA binding sites16,17,19,36. We used 15 biotin-
labelled antisense DNA oligonucleotides (oligos) spanning across
MEG3 RNA (Supplementary Fig. 6a) to ensure robust capture of
MEG3 RNA-associated genomic loci with streptavidin beads. The
ChOP pull-down using MEG3 antisense oligos detected speciﬁc
enrichment of the MEG3 RNA, but not abundantly expressed
nuclear-enriched MALAT1 lncRNA, whereas pull-down with a
biotin probe against green ﬂuorescence protein (GFP) RNA
(with no known target in the human genome), used as a negative
control, detected neither MEG3 nor MALAT1, highlighting the
speciﬁcity of the ChOP pull-down assay (Fig. 4a). We then
subjected the ChOP pull-down chromatin material with MEG3
and control probes to high-throughput DNA sequencing. By
considering the MEG3-enriched regions over input and
nonspeciﬁc GFP probes, we detected 6,837 MEG3-bound
genomic regions associated with 5,622 genes (Table 2), as
identiﬁed using the GREAT tool37. We found a signiﬁcant
overlap between the deregulated genes from the microarray
experiment following MEG3 downregulation and the genes
associated with MEG3 peaks (300 genes, Po5e 14,
hypergeometric distribution), indicating a functional role
of the MEG3 peaks in the regulation of associated genes
(Table 2, Supplementary Fig. 6b, Supplementary Data 8 and
Supplementary Data 9). We also observed a signiﬁcant overlap
between the deregulated genes from RNA sequencing or from
both microarray and RNA sequencing experiments, and the genes
associated with MEG3 peaks (Supplementary Fig. 6b,c). When we
performed network analysis with the 300 deregulated genes
associated with theMEG3 peaks, we found that TGF-b was one of
the major affected pathways (Supplementary Fig. 7a,b). The
majority of the MEG3-bound peaks associated with the
deregulated genes were located distal to the promoter, including
genes involved in the TGF-b pathway (Table 2, Fig. 4b and
Supplementary Fig. 8a-o), suggesting that the MEG3-bound
regions may serve as distal regulatory elements, and that the
MEG3/EZH2 functional interaction contributes to their
regulation. To verify whether the enrichment of the MEG3-
bound regions is due to an artefact of direct interaction between
the MEG3 genomic locus and the MEG3 peaks identiﬁed, we
performed ChOP using sense and antisense oligos. We validated
the enrichment of the MEG3 peaks associated with the TGF-b
pathway genes in ChOP pull-down with the antisense oligos but
not with the sense oligos. The enrichment with antisense oligos
was lost when the chromatin was pretreated with RNase A
(Supplementary Fig. 9a). This further suggests that the pull-down
with antisense oligos is mediated by MEG3 RNA rather than
being the result of technical artefacts. To identify MEG3-bound
peaks that overlap with putative enhancers in BT-549 cells, we
performed H3K4me1 ChIP-seq and overlapped the H3K4me1
peaks with MEG3 peaks, and found that 662 MEG3 peaks
overlapped with H3K4me1 peaks (H3K4me1/MEG3 peaks) in
BT-549 cells (Table 2). The H3K4me1/MEG3 peaks’ associated
genes showed a signiﬁcant overlap with the genes that were
deregulated upon downregulation of MEG3 and had at least one
associated MEG3 peak (Table 2 and Supplementary Fig. 6c).
We observed a decrease in the enrichment of both H3K27me3
and EZH2 over the distal MEG3-bound peaks of the TGF-b
pathway genes upon downregulation of MEG3 (Fig. 4c and
Supplementary Fig. 9b), suggesting that MEG3 is required for
PRC2 recruitment and H3K27me3 maintenance at the distal
regulatory elements. We tested the enhancer activity of the
TGFBR1-associated H3K4me1/MEG3 peaks using the luciferase
system and found a signiﬁcant increase in the enhancer activity of
the peaks in the MEG3 shRNA-transduced cells compared with
the control shRNA cells (Supplementary Fig. 9c). We performed
the chromosome conformation capture (3C) assay to measure the
Table 1 | KEGG pathway analysis of the deregulated genes identiﬁed by microarray and RNA-sequencing after downregulation of
MEG3 and EZH2 by siRNA in BT-549 cells using GeneSCF.
KEGG-ID KEGG pathways MEG3 (P value) EZH2 (P value)
Microarray RNA-seq Microarray RNA-seq
hsa05200 PI3K-Akt signalling pathway 0.0000000307 0.00036 0.0001 0.00000376
hsa04390 Proteoglycans in cancer 0.000000472 0.00494 0.00000787 0.0021
hsa05166 Pathways in cancer 0.00000099 0.000000697 0.00000808 0.002
hsa04350 TGF-beta signalling pathway 0.0000059 0.0000893 0.00000062 0.0002
hsa05205 HTLV-I infection 0.00000865 0.00000239 0.0002 0.0432
hsa04151 Focal adhesion 0.0000188 0.00076 0.0005 0.0000239
hsa04910 Insulin signalling pathway 0.0000246 0.0175 0.0087 0.0274
hsa04510 Hippo signalling pathway 0.0000867 0.000002029 0.0001 0.0022
hsa01100 Colorectal cancer 0.0001 0.0017 0.000029 0.0009
hsa05414 Regulation of actin cytoskeleton 0.0003 0.0001 0.0012 0.0000114
hsa04010 Endocytosis 0.0005 0.0000187 0.0002 0.0002
hsa00532 Pancreatic cancer 0.0008 0.01 0.0002 0.0000439
hsa04668 Hypertrophic cardiomyopathy 0.0013 0.00000569 0.0053 0.0238
hsa05203 Chagas disease 0.0013 0.0028 0.000022 0.0054
hsa04520 Adherens junction 0.0016 0.0002 0.000079 0.0005
hsa05142 Viral carcinogenesis 0.0017 0.0144 0.0082 0.0177
hsa05410 TNF signalling pathway 0.0019 0.00107 0.0052 0.0001
hsa05212 Glycosaminoglycan biosynthesis 0.0027 0.002 0.0311 0.0136
hsa04144 MAPK signalling pathway 0.0062 0.0004 0.014 0.0001
hsa04810 Dilated cardiomyopathy 0.02 0.0000489 0.0013 0.0289
hsa05210 Metabolic pathways 0.04 0.0269 0.0009 0.0216
siRNA, small interfering RNA; TGF, transforming growth factor.
*P value represents Fisher’s exact test and obtained using GeneSCF (see Methods section).
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long-range interactions between the upstream H3K4me1/MEG3
peaks and the TGFBR1 promoter. In our 3C experiment, we
detected interaction between the upstream H3K4me1/MEG3
peaks and the TGFBR1 promoter. Interestingly, these interactions
were enhanced in the MEG3 shRNA-transduced cells compared
with the control shRNA cells (Fig. 4d), indicating that the MEG3/
PRC2 functional interaction could regulate the activity of the
distal regulatory elements.
MEG3 targets the TGF-b pathway genes via GA-rich sequences.
We next tried to investigate the mechanisms that facilitate
how MEG3 lncRNA selects its target regions across the genome.
First, we looked for common sequence motifs enriched in the
MEG3-bound genomic regions and identiﬁed a strong GA-rich
sequence motif that was overrepresented among the 6,837 MEG3
peak summits (motif e-value: 1.7e 976) (Fig. 5a). The GA-rich
motif was also overrepresented among the 532 MEG3 peaks
(motif e-value: 6.3e 904) associated with the MEG3-deregulated
genes (Fig. 5a), suggesting that the GA-rich repeat may play a
functional role in targeting of the MEG3 RNA to chromatin.
Interestingly, by using the ChIRP technique, similar GA-enriched
motifs were identiﬁed among the binding sites of the chromatin-
modulating RNAs roX2 and HOTAIR, indicating that GA-enri-
ched motifs may play an important role in the targeting of
lncRNAs across the genome19. Previously, several studies using
different techniques have shown that GA-rich homopurine
sequences can form triplex structures38–40. Overrepresentation
of GA-rich sequences among the genomic binding sites of the
lncRNAs analysed (MEG3, HOTAIR and roX) raises the
possibility that the lncRNAs may be recruited to their target
genes via RNA–DNA triplex formation. By using Triplexator
software41 (which can predict triplex target sites, TrTS), we found
a greater number of the predicted TrTS in the MEG3 peak
summit (±200 bp from the centre of the peak) than the ﬂanking
sequences (200 bp upstream and 200 bp downstream of the peak
summit; Fig. 5b). Triplexator was also used to scan for triplex-
forming oligonucleotides (TFOs) within the MEG3 RNA, and
several TFOs with high scores were detected. Interestingly, the
TFOs with high scores are also enriched with GA-rich sequences
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Figure 4 | Genome-wide mapping of MEG3 lncRNA binding sites. (a) RT–qPCR analysis showing speciﬁc enrichment (presented as percentage of input)
ofMEG3 but notMALAT1 RNA in the ChOP pull-down assay withMEG3 antisense probes. The ChOP pull-down with GFP antisense oligo, used as a negative
control, did not show any enrichment of MEG3 and MALAT1 RNAs. (b) Genomic tracks showing ChOP-seq (MEG3, GFP and input) and ChIP-seq
(H3K4me1) intensities, visualized in log scale. The MEG3 binding site is located upstream of the TGFBR1 gene (falls within the intron of the COL15A1 gene)
and it overlaps with H3K4me1 peaks in BT-549 cells. (c) ChIP–qPCR showing enrichment of H3K27me3 chromatin marks, presented as percentage of input,
over the MEG3 peaks associated with the TGF-b genes in Ctrlsh and MEG3sh cells (±s.d., n¼ 3). (d) Schematic outline of the TGFBR1 gene showing MEG3
peaks and the location of 3C primers (P1–P9), as indicated by arrows. EcoRI restriction sites are shown as blue vertical lines. Each error bar
represents±s.d. from three experiments. Looping events between the upstream MEG3 binding site (corresponding to P2 primer) and the TGFBR1 promoter
detected by 3C–qPCR in Ctrlsh andMEG3sh cells. The P values were calculated using Student’s t-test (two-tailed, two-sample unequal variance), *Po0.05.
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(Table 3), indicating that the GA-rich sequences from target
genes and MEG3 RNA could form triplex structures by forming
Hoogsteen bonds between RNA and DNA. To test the ability of
MEG3 lncRNA to form triplex structures, we used a 20-
nucleotide-long GA-rich RNA oligo (hereon referred to as
MEG3 TFO) located at the 50-end of the MEG3 RNA and its
sequence overlap with the TFOs (TFO1, TFO2 and TFO3) with
high score that were identiﬁed by Triplexator (Fig. 5c and
Table 3). Using electrophoretic mobility shift assay, we tested the
triplex-forming ability of the MEG3 TFO (single-stranded RNA,
ssRNA) with the GA-rich (double-stranded DNA, dsDNA)
MEG3 peak sequences associated with the selected TGF-b
pathway target genes (TGFBR1, TGFB2 and SMAD2) in vitro
(Fig. 5d). Consistent with the Triplexator predictions, we
observed a shift in the end-labelled GA-rich dsDNA sequences
when incubated with increasing concentrations of the MEG3
TFO, indicating triplex formation between the MEG3 TFO and
the GA-rich MEG3 peak summits (Fig. 5d, compare lane 1 with
lanes 2 and 3), but not with a control RNA oligo selected from the
MEG3 lncRNA with no GA bias (Fig. 5d, compare lane 1 with
lanes 8 and 9). The triplex structures were sensitive to RNase A
treatment but were resistant to RNase H digestion (Fig. 5d, lanes
4 and 5, respectively), while an in vitro formed RNA–DNA
hybrid was digested by RNase H (Supplementary Fig. 10a). These
results together suggest that the observed shift was not because of
Watson–Crick RNA–DNA pairing. We also observed that these
shifts were affected when speciﬁc competitor (the same GA-rich
dsDNA oligo, unlabelled) was used but were unaffected by
nonspeciﬁc competitor (unlabelled control dsDNA oligo; Fig. 5d,
compare lane 6 with 7). We did not observe any complex
formation between MEG3 TFO incubated with end-labelled
control DNA sequences (with no GA bias) or control RNA
incubated with control DNA sequences (Supplementary
Fig. 10b,c). To further check the speciﬁcity of the interaction
between MEG3 TFO and GA-rich DNA sequences, we mutated
the core sequences of the TGFBR1-associated MEG3 peak and
found that triplex formation was compromised between the
mutant TGFBR1 dsDNA oligo and the MEG3 TFO (Fig. 5e).
These observations suggest that MEG3 may be recruited to
genomic loci through the formation of RNA–DNA triplex
structures. We predicted the triplex-forming ability of GA-rich
motifs of another chromatin-interacting lncRNA, HOTAIR, and
found more Triplexator-predicted TrTS from the HOTAIR
summit regions than from the neighbouring sequences
(Supplementary Fig. 10d,e).
We then investigated the formation of RNA–DNA triplex
structures by using an alternative method whereby biotin-labelled
MEG3 TFO and a control RNA oligo were either used to transfect
BT-549 cells (Fig. 5f) or incubated with nuclei isolated from
BT-549 cells (Fig. 5g). Upon pull-down with streptavidin magnetic
beads, we found signiﬁcant enrichment of the selectedMEG3 peaks
associated with the TGF-b genes—with MEG3 TFO compared
with control oligo. The enrichment of the MEG3 target sequences
was unaltered upon treatment with RNase H, suggesting that the
interaction of theMEG3 TFO with the target DNA sequence is not
mediated by Watson–Crick RNA–DNA pairing (Fig. 5f,g). We
next investigated whether the MEG3 TFO occupancy at the MEG3
target genes alters their transcriptional regulation. To this end, we
analysed expression of the three key TGF-b genes TGFB2, TGFBR1
and SMAD2 in BT-549 cells after transfection with MEG3 TFO or
control RNA oligo. We found that expression of the TGF-b
pathway genes was marginally, but signiﬁcantly, upregulated in the
MEG3 TFO-transfected cells compared with the cells transfected
with control oligo (Fig. 5h). These results indicate that the MEG3
TFO sequence can compete with endogenous full-length MEG3
RNA in binding to MEG3 target sites, thus affecting the
endogenous function of MEG3 RNA.
We also performed circular dichroism (CD) spectroscopy to
investigate the triplex-forming ability of some of the MEG3 target
sites with MEG3 TFO. Figure 5i (left) shows the CD spectrum of
the dsDNA oligo corresponding to the TGFB2-associated MEG3
peak incubated with MEG3 TFO ssRNA and the corresponding
spectrum with a control ssRNA. The spectrum of the MEG3 TFO
sample has some distinct features, such as a distinct blue-shift
(B10 nm) of the peakB270–280 nm and a strong negative peak
at B210 nm, which are not seen in the sample containing the
control ssRNA. The effect is emphasized in the inset in Fig. 5i,
Table 2 | Summary of MEG3 peaks with associated genes
and their overlap with H3K4me1 peaks in BT-549 cells.
Summary of the MEG3 binding sites
in BT-549 cells
No.
of
peaks
No. of
genes
associated
MEG3 binding sites in BT-549 cells 6,837 5,622
Number of MEG3 peaks in promoter 217 173
Number of MEG3 peaks in promoter–distal region 6,620 5,449
Peaks associated with MEG3-deregulated genes
(MEG3-deregulated peaks)
532 300
Number of MEG3-deregulated peaks in distal 524 292
Distal MEG3 peaks overlap with BT-549
H3K4me1 peaks
662 959
Distal MEG3-derugulated peaks overlap
with BT-549 H3K4me1 signals
56 52
Figure 5 | MEG3 lncRNA regulates its target genes through triplex structure formation. (a) Predicted GA-rich motifs enriched in all MEG3 peaks and
peaks associated with deregulated genes using MEME-ChIP. (b) Number of TrTS over the MEG3 peak summits and neighbouring regions, predicted by
Triplexator41. (c) The schematic shows the MEG3 TFO used in the triplex assays. The exons are colour-coded as described before. (d) Electrophoretic
mobility shift assay. End-labelled dsDNA oligos (sequences provided in the schematic with gene name) were incubated alone (lane 1) or with increasing
concentrations of MEG3 ssRNA TFO (lanes 2 and 3: shift indicated with arrow) or with increasing concentrations of control ssRNA oligo (lanes 8 and 9).
dsDNA oligos were incubated with MEG3 TFO and treated with either RNase A (lane 4) or RNase H (lane 5). dsDNA oligos were incubated with MEG3
ssRNA TFO in the presence of either unlabelled speciﬁc competitor (lane 6) or nonspeciﬁc competitor (lane 7). (e) TGFBR1-associated MEG3 peak
sequence and its mutated version (the changed nucleotides are in red) were incubated alone (lanes 1 and 7) or with MEG3 TFO. Arrow indicates complex
formation. (f,g) Enrichment of MEG3 peak sequences using biotin- and psoralen-labelled MEG3 TFO. RNase H-treated lysates were used to capture the
labelled MEG3 TFO using streptavidin beads. The enrichment of MEG3 peaks is presented as the ratio between MEG3 TFO and control oligo (±s.d., n¼ 3).
(h) RT–qPCR analysis of gene expression in BT-549 cells transfected with either MEG3 TFO or control RNA oligo. Expression in MEG3 TFO presented
relative to the control oligo (±s.d., n¼ 3). *Po0.05, Student’s t-test (two-tailed, two-sample unequal variance). (i) Left panel: CD spectra of a 1:1 mixture
of TGFB2 dsDNA and MEG3 TFO (ssRNA) are shown in black, and TGFB2 dsDNA and the control ssRNA are shown in red. Right panel: the sum of the
individual CD spectra for TGFB2 dsDNA and MEG3 TFO (ssRNA) is shown in black, and the sum of the individual CD spectra for TGFB2 dsDNA and the
control ssRNA is shown in red. Inset in the left and right panel shows the difference between the two spectra.
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where we show the difference in CD spectrum between the
TGFB2 dsDNA oligo with the MEG3 TFO and the control
ssRNA. These two features, and especially the strong negative
peak atB210 nm, are often seen for TFOs42–44. Figure 5i (right)
shows the sum of the individual CD spectra for either TGFB2
dsDNA and MEG3 TFO (ssRNA) or TGFB2 dsDNA and the
control ssRNA. For these artiﬁcial spectra, the difference between
the MEG3 TFO and the control ssRNA is much smaller (Fig. 5i,
right, inset), supporting our conclusion that the change in CD
spectrum when MEG3 TFO is incubated with the dsDNA TGFB2
5′ 3′
-3′5′- MEG3 TFO
MEG3
b cPeak summit (400 bp)
Neighbouring
gsequence
(400 bp) 
0
500
1,000
1,500
2,000
2,500
N
um
be
r o
f p
re
di
ct
ed
 T
rT
S
200 bp200 bp 200 bp 200 bp
3 4 5 6 7 8 9
d e
SMAD2-associated MEG3 peak
+
TGFBR1-associated MEG3 peak 
MEG3 TFO
(3′        5′ )
+
DNA probe {
TGFB2-associated MEG3 peak
+
MutantTGFBR1-associated MEG3 peak
+
1 2 3 4 5 6 7 8 91 2 3 4 5 6 7 8 91 2 3 4 5 6 7 8 9 10 11121 2
0
5
10
15
20
25
No RNase H
With RNase H
Actin
(negative
control)
En
ric
hm
en
t o
ve
r c
on
tro
l R
N
A 
o
lig
o
In vivo triplex capture
MEG3  peaks associated genes
Streptavidin
BiotinPsoralen
Ultraviolet
irradiation
MEG3 TFO
(Transfected into the cell or
incubated with nuclei)
f
TGFBR1 TGFB2 SMAD2
MEG3  peaks associated genes
20
0
5
10
15
20
25
30
In vivo triplex capture
No RNase H
With RNase H
Actin
(negative
control)
En
ric
hm
en
t o
ve
r c
on
tro
l R
N
A 
o
lig
o
g
TGFBR1 TGFB2 SMAD2
0
40
60
80
100
120
140
160
Control oligo
MEG3 TFO 
*
*
*
TG
FB
R1
SM
AD
2
R
el
at
iv
e 
ex
pr
es
sio
n
RT-qPCR
h
ME
G3
TG
FB
2
i
Wavelength (nm)
200 250 300
–100
–50
0
50
100
CD
 / 
( d
eg
 M
–
1 )
–100
–50
0
50
100
–100
–50
0
50
100
Wavelength (nm)
250 300200
–100
–50
0
50
100
TGFB2 TGFB2
200 250 300 200 250 300
ΔC
D 
/ ( 
de
g M
–
1 )
ΔC
D 
/ ( 
de
g M
–
1 )
CD
 / 
( d
eg
 M
–
1 )
All MEG3 peak
Motif e-value < 1.7e–976
Bi
t
2
1
0 1 2 3 4 5 6 7 8 9 10
bi
t
2
1
0
Peaks associated with
deregulated genes
Motif e-value < 6.3e–904 
a
1 2 3 4 5 6 7 8 9 10
Neighbouring
sequence
(400 bp) 
MEG3
summit
(400 bp) 
′- ′-
′-
′-
′-
′-
′-
′-
′-′-
-
′-
′-
′
- ′
- ′ - ′
- ′
- ′
- ′
- ′
- ′ - ′
- ′
- ′
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8743 ARTICLE
NATURE COMMUNICATIONS | 6:7743 | DOI: 10.1038/ncomms8743 | www.nature.com/naturecommunications 11
& 2015 Macmillan Publishers Limited. All rights reserved.
is owing to a speciﬁc interaction between the two. We thus
interpret the CD data, in combination with evidence from the
complementary techniques, as being owing to the formation of a
triplex structure between the dsDNA TGFB2 and the MEG3 TFO
ssRNA. CD spectra similar to the ones in Fig. 5i (left) were also
detected with the SMAD2- (Supplementary Fig. 11a) and TGFBR1
(Supplementary Fig. 11b)-associated MEG3 peaks, indicative of
triplex formation.
Triplex structures are associated with TGF-b genes in vivo.
Our in vitro triplex formation assay with MEG3 RNA TFO and
GA-rich MEG3 target sequences suggests that RNA–DNA
triplex formation could guide MEG3 lncRNA to its target genes
across the genome. This raises an intriguing question as to
whether RNA–DNA triplex structures are present in vivo. In
order to identify such triplex structures in BT-549 cells, we
wanted to perform immunostaining with anti-triplex dA.2rU
antibody, which can detect triplex structures. The speciﬁcity
of the dA.2rU antibody in detecting triplex structures has
been veriﬁed by enzyme-linked immunosorbent assay45,46. In
addition, anti-triplex dA.2rU antibody has been used in
immunostaining to detect the triplex structures on polytene
chromosomes, and also in two-cell early pre-implantation mouse
embryos45,47. Since the anti-triplex dA.2rU antibody was raised
against the triplex derived from homopolymeric nucleic acids
(poly(rU).poly(dA).poly(rU) complex)46, we wanted to test the
ability of the anti-triplex dA.2rU antibody to recognize non-
homopolymeric triplexes, which would be relevant for detecting
triplex structures in vivo. For this, we performed immunodots
with DNA triplexes built from poly-purine/poly-pyrimidine
sequences, including controls for the antibody reactivity. As
expected, the antibodies recognized homopolymeric triplexes
containing a poly(dA) backbone and did not bind to nucleic acids
when non-complementary sequences in solutions impeded
formation of triple-stranded complexes. Also, the antibodies
clearly bound to the triplex DNA made with poly-purine/poly-
pyrimidine sequences (Supplementary Fig. 12a), indicating that
antibody reactivity is not restricted to three-stranded
conﬁgurations assembled with homopolymeric nucleic acids. To
detect triplex structures in vivo, immunostaining was performed
on BT-549 cells with anti- triplex dA.2rU antibody, and speciﬁc
staining was observed with anti- triplex dA.2rU antibody
(Fig. 6a). The anti-triplex staining was distributed in both the
nucleus and the cytoplasm with more enrichment of the triplex-
speciﬁc staining in the nuclear compartment (Fig. 6a). Triplex-
speciﬁc staining was signiﬁcantly reduced in the cells treated with
RNase A (Fig. 6b, left and middle panel), but it was resistant to
treatment with RNase H, which speciﬁcally cleaves RNA–DNA
hybrids (Fig. 6b, right panel). The triplex staining pattern in
BT-549 cells was similar to the staining of triplex structures that
had been detected previously in human cells using a monoclonal
anti-triplex antibody, Jel 318 (ref. 48 and Supplementary
Fig. 12b). Although the triplex structures were more enriched
in the nucleus, we detected triplex-speciﬁc staining in the
cytoplasm, which could be due to recognition of the triplex
structures present in mitochondria49,50. To test this, we labelled
the mitochondria in BT-549 cells with MitoTracker followed by
immunostaining with anti-triplex antibody. We indeed observed
a co-localization of the mitochondrial staining with triplex signals
from cytoplasm, suggesting that a part of the cytoplasmic triplex
signals are contributed by the triplex structures present in
mitochondria (Supplementary Fig. 12c). We next wanted to
determine whether the triplex structures present at the MEG3
binding sites are associated with the TGF-b pathway genes in BT-
549 cells. We performed triplex-ChIP with anti-triplex dA.2rU
antibody and observed enrichment of the selected MEG3 peaks
associated with the TGFBR1, TGFB2 and SMAD2 genes. To check
the speciﬁcity of the anti-triplex dA.2rU pull-down, we pretreated
the chromatin with either RNAse H or RNase A. RNase A
treatment, but not RNase H, treatment resulted in complete loss
of triplex enrichment (Fig. 6c). We also performed triplex-ChIP
inMEG3-downregulated BT-549 cells and found a decrease in the
enrichment of the triplex structures over the MEG3 peaks
associated with the TGFBR1, TGFB2 and SMAD2 genes,
suggesting that the MEG3 lncRNA regulate these genes through
triplex formation (Fig. 6d).
Chromatin-binding region of MEG3 is functionally distinct.
We wanted to determine whether the MEG3 RNA sequences
required for the PRC2 interaction and RNA–DNA triplex for-
mation are functionally distinct. For this purpose, we generated a
MEG3 mutant by deleting the core MEG3 TFO (the TFO used in
the triplex assay above) containing GA-rich sequences and named
this D46-56 MEG3 (46–56 indicates the position of the nucleo-
tides with respect to the 50-end of MEG3). We found that the
TFO deletion had no effect on the interaction of PRC2 with
MEG3 (Fig. 7a). Considering that D345-348 MEG3 affects the
PRC2 interaction of WT MEG3 (Figs 7a and 2e), we decided to
test the chromatin-interacting property of the WT and MEG3
RNAs with deletions (D46-56 MEG3 and D345-348 MEG3) by
transfecting BT-549 cells with in vitro-synthesized biotin-labelled
WT or mutantMEG3 RNAs (D46-56MEG3 or D345-348MEG3).
We found that the WT and D345-348 MEG3 RNAs could pull-
down MEG3 peak sequences associated with the TGF-b genes
(TGFB2, TGFBR1 and SMAD2), but not when the pull-down was
performed with the D46-56 MEG3 TFO deletion (Fig. 7b). This
suggests that the decrease in the association between MEG3 and
PRC2 does not have any effect on the chromatin-binding prop-
erty of MEG3 RNA. Taken together, these observations indicate
that the chromatin targeting and PRC2 interaction properties of
MEG3 lncRNA are mediated by distinct RNA sequences (Fig. 7c).
Discussion
Previous studies have identiﬁed thousands of lncRNAs that
interact with repressive chromatin modiﬁers such as EZH2
(refs 24,25). The interaction of lncRNAs with chromatin
modiﬁers suggests that lncRNAs may have a role in targeting
the chromatin modiﬁers to chromatin. LncRNA-mediated recruit-
ment of the chromatin modiﬁers to chromatin is exempliﬁed by
Kcnq1ot1 and HOTAIR lncRNAs, which have been shown to
interact with chromatin and recruit repressive chromatin modiﬁer
EZH2 (refs 10,19,23,51). This raises the possibility that there could
be many more lncRNAs that interact with chromatin and serve as
a link between chromatin and chromatin modiﬁers. Use of
Table 3 | TFOs predicted by Triplexator.
OligoID TFOs (50–30) Score
TFO1 GGAGAGcAGAGAGGGAGcG 18
TFO2 GGcGGAGAGcAGAGAGGGAGcG 19
TFO3 AGAcGGcGGAGAGcAGAGAGGGAG 21
TFO4 AGGAtGGcAAAGGAtGAAGAGGA 20
TFO5 AAAtGAGAtAAAAGAGG 15
TFO6 GTcTTTGcTTGTGTT 13
TFO7 TGGGTGGGcTTcTGG 13
TFO8 TaGGGTTGTTGTGaG 13
TFO9 GGGcTGTTGTGaGGGG 14
TFOs, triplex-forming oligos; Score, triplex-forming potential scores.
The bold nucleotides indicate overlap with MEG3 TFO with high score.
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antibodies to EZH2 and its catalysed repressive chromatin mark
H3K27me3 in our ChRIP-seq enabled us to identify 276
chromatin-interacting lncRNAs that are enriched in both EZH2
and H3K27me3 puriﬁed chromatin fractions. We expect that these
chromatin-interacting lncRNAs will be a valuable resource for
future investigations aimed at understanding the molecular
mechanisms that dictate association of lncRNAs with chromatin.
Indeed, by using one of the repressive chromatin-interacting
lncRNAs, MEG3, we have characterized the mechanisms by which
MEG3 lncRNA is guided to chromatin. Deciphering of the
mechanisms that guide the EZH2-interacting lncRNAs to
repressive chromatin will also shed light on how the PRC2
complex is targeted across the genome in an RNA-dependent
manner. Repressive chromatin-associated lncRNAs also include
several lncRNAs (PCA3, GAS6-AS1, CECR7 and BDNF-AS1) that
have been implicated in cancer or other cellular functions, and
among this BDNF-AS1 lncRNA has been shown to regulate gene
expression by recruiting PRC2 (refs 30,52–54).
Mapping of the MEG3 binding sites across the genome in
BT-549 cells revealed that the majority of MEG3 target sites are
located distal to the promoter regions. Interestingly, a signiﬁcant
proportion of the promoter–distal MEG3 binding sites are
enriched with enhancer chromatin marks. More importantly,
we observed that the interaction between the TGFBR1 gene
promoter and a putative enhancer increased signiﬁcantly in the
absence of MEG3. In addition, the downregulation of MEG3 also
resulted in loss of EZH2 and H3K27me3 enrichment at the
putative enhancer. These results suggest that the MEG3 lncRNA
modulates the activity of the putative enhancer by regulating
chromatin structure, thereby ﬁne-tuning gene expression.
We detected over 6,800 MEG3 binding sites, and a proportion
of these MEG3 peaks were associated with the genes that were
either upregulated or downregulated after MEG3 knockdown in
BT-549 cells. Given the association of MEG3 with a repressive
chromatin modiﬁer, EZH2, one would expect that the upregu-
lated genes are more direct targets of the MEG3/EZH2
interaction. On the other hand, MEG3 peaks also ﬂanked the
genes that showed repression in the absence of MEG3. We
suggest that the expression of these genes may be facilitated by
the recruitment of EZH2 by MEG3, and this EZH2-dependent
activation of genes was evident in recent ﬁndings where EZH2
has been shown to act as a coactivator of gene expression in
prostate and breast cancer cells55,56. Although MEG3-regulated
genes were enriched in the MEG3 peaks, there was no one-to-one
correlation between the MEG3 peaks and associated genes. This
could be explained in part by the non-reversible nature of
noncoding RNA-mediated chromatin modiﬁcation; that is, once a
chromatin mark is established in an RNA-dependent manner, it
is maintained in the absence of the RNA57. The stable
maintenance of RNA-mediated repressive modiﬁcation after
establishment was also observed with Kcnq1ot1 lncRNA-
mediated silencing, where the RNA was removed conditionally
after the repressive chromatin was established58. It is possible that
a similar mechanism exists in trans-acting lncRNAs such as
MEG3, where RNAi-mediated knockdown of the lncRNA
does not lead to deregulation of all its target genes because of
RNA-independent maintenance of the chromatin structure.
We have explored the molecular mechanisms by which MEG3
lncRNA contributes to regulation of the TGF-b pathway. We
found that the genes of the TGF-b pathway are direct targets of
MEG3, and that it regulates these genes by binding to promoter–
distal regulatory regions. Consistent with our results, a recent
investigation has found thatMEG3 expression was downregulated
upon TGF-b1 treatment in human hepatic stellate cells, and
that MEG3 overexpression inhibited the TGF-b1-stimulated
cell proliferation and induced apoptosis59. These observations
together with our data indicate the existence of a probable
feedback loop between the MEG3 and TGF-b pathway. This
target recognition by MEG3 occurs via triplex formation between
GA-rich sequences of target genes and GA-rich sequences within
MEG3 lncRNA. Interestingly such as MEG3, the HOTAIR
binding sites also have GA-rich sequences19. Formation of
triplex structures between MEG3 lncRNA and GA-rich
sequences in our triplex assays indicates that GA-rich sequences
may guide lncRNAs to their target genes. Immunostaining with
monoclonal antibody to triplex structures revealed that these
structures are widespread in vivo. Furthermore, using Triplex-
ChIP assay, we found that triplex structures were present in vivo
over the MEG3 peaks associated with the TGF-b pathway genes.
Taken together, these observations further suggest that targeting
of MEG3 lncRNA to chromatin occurs through RNA–DNA
triplex formation. Our observation on the mode of the chromatin
targeting of MEG3 through RNA–DNA triplex formation along
with the previous evidence of triplex-mediated communication of
lncRNAs with their target genes suggests that this type of
mechanism may be more general38,60–63. Similar to the trans-
acting role of human MEG3 in breast cancer cells, a recent
investigation by Kaneko et al.29 demonstrated that interaction
between JARID2 and MEG3 lncRNA is critical for targeting of
PRC2 complexes to multiple genes in trans in mouse embryonic
stem cells. As JARID2 has also been found to play a critical role in
activating the catalytic function of PRC2 by weakening the RNA–
PRC2 interaction, it would be interesting to investigate whether
JARID2 has any such role in regulation of human MEG3–PRC2
interaction as well64. In this context, our study is particularly
signiﬁcant, as it contributes to our understanding of the
mechanisms underlying the lncRNA-mediated targeting of
PRC2 complex across the genome.
Functional overlap between MEG3- and EZH2-deregulated
genes, and mapping of a signiﬁcant number of MEG3 binding
sites to MEG3-deregulated genes indicate that MEG3 has a
functional role in guiding PRC2 to its target genes across the
genome. Fine-mapping of MEG3 RNA sequences required for
PRC2 interaction and chromatin targeting via triplex formation
suggests that while the triplex-forming sequences may guide
MEG3 lncRNA to chromatin, the PRC2-interacting sequences
facilitate the recruitment of PRC2 to promoter–distal regulatory
regions, thereby depositing H3K27me3 to modulate trans-
criptional activity (Fig. 7c). Our data on MEG3 RNA together
with the published data on HOTAIR indicate that the GA-rich
homopurine motif may be the preferred binding site for
both MEG3 and HOTAIR lncRNAs. Interestingly, the GA-rich
motif is also present in Drosophila65,66, Arabidopsis67 and
mammalian68,69 polycomb response elements. In Drosophila
melanogaster, PRC2 recruitment to the GA-rich motif has
previously been shown to occur via a DNA-binding trans-
cription factor, but no such factor has been characterized in
mammals65. GA-rich motifs may be preferred sequences for
RNA-dependent PRC2 recruitment, and thus lncRNAs may
bypass the requirement for protein factors in PRC2 recruitment.
Methods
Molecular cloning. Full-length MEG3 cDNA was ampliﬁed from BT-549 nuclear
RNA and cloned into either pCMV6-XL5 (OriGene) or pREP4 episomal vector
(Life Technologies) using the primers described in Supplementary Data 10. The
details of the exon compositions of the full-length MEG3 clone are provided in the
Results section. Mutant MEG3 RNAs (D340-348, D345-348 and D46-56 MEG3)
described in the manuscript were generated using the Quik-change site-directed
mutagenesis kit (Agilent Technologies). Primers used in the site-directed muta-
genesis and for cloning of MEG3 are provided in Supplementary Data 10. For
in vitro transcription of biotin-labelled and unlabelled MEG3 RNA, full-length
MEG3 (referred to as WT MEG3) or the mutant MEG3 RNAs, carrying various
deletions, were cloned into pGEM-T Easy vector (Promega).
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Transfection and RT–qPCR assay. siRNAs were used for transfection using
Lipofectamine RNAiMAX reagent (Life Technologies). For each siRNA transfec-
tion, 50,000 BT-549 or HF cells were seeded per well in 24-well plates 12–16 h
before transfection. siRNAs against MEG3 and EZH2 or the control siRNA were
used for transfection at a ﬁnal concentration of 65 nM (details of siRNAs are
provided in Supplementary Data 10). Forty-eight hours after transfection, RNA
was isolated using the ReliaPrep RNA isolation kit (Promega). DNase I-treated
RNA (500 ng) was converted to cDNA using reverse transcriptase (Promega) and
assayed for gene expression by SYBR Green-based RT–qPCR using the Vii7 Real-
Time PCR system (Life Technologies) with the relevant primers listed in
Supplementary Data 10. A negative control reaction without any cDNA was
included in every qPCR. Episomal pREP4 plasmids (only pREP4 vector or pREP4
containing MEG3) were used to transfect BT-549 cells using Lipofectamine 2000
reagent (Life Technologies) and overexpression ofMEG3 RNA was veriﬁed by RT–
qPCR 48 h after transfection, using primer pairs overlapping MEG3 exon 3 (primer
sequences are provided in Supplementary Data 10). pCAG-hEZH2 or the control
DNA plasmid was used to transfect BT-549 cells using Lipofectamine 2000. EZH2
overexpression was conﬁrmed by RT–qPCR 48 h after transfection, using primer
pairs provided in Supplementary Data 10.
Cell culture and generation of stable clones. BT-549 cells were maintained in
RPMI (Sigma) supplemented with 10% fetal bovine serum (FBS) (Sigma). MDA-
MB-231 and HF cells were maintained in DMEM (Invitrogen) with 10% FBS. BT-
549 cells were procured from CLS cell line service. MDA-MB-231 cells were kindly
gifted by Dr Briegel Karoline (University of Miami Miller School of Medicine,
Miami, USA) and HF cells were kindly gifted by Dr Bengt Westermark (Uppsala
University, Uppsala, Sweden). MISSION lentiviral transduction particles expres-
sing non-target shRNA control or shRNA againstMEG3 were obtained from Sigma
(the sequences are provided in Supplementary Data 10) and were used for trans-
duction following the manufacturer’s protocol. BT-549 cells (5 104) were plated
in the wells of 24-well plates and transduced with either control or MEG3 shRNA
lentiviral particles. Lentivirus-transduced BT-549 cells were selected with pur-
omycin to obtain stably integrated shRNA vectors. The stable clones were main-
tained thereafter in RPMI containing puromycin (1 mgml 1). We veriﬁed the
downregulation of theMEG3 lncRNA in lentivirus-transduced stable clones by RT-
qPCR. Stable clones of MDA-MB-231 cells containing pREP4MEG3 were gener-
ated after antibiotic selection with hygromycin (850 mgml 1), and maintained in
DMEM containing hygromycin (850 mgml 1). We veriﬁed the overexpression of
the MEG3 RNA in MDA-MB-231 stable clones by RT–qPCR following the same
procedure as described above.
ChRIP-seq. ChRIP was performed using BT-549 cells adapting the protocols from
Mondal et al.28 and Kuo et al.70 with the modiﬁcations as detailed below. BT-549
cells were plated on tissue culture dish (7–8 million cells per 150mm plate) and
incubated overnight (14–16 h) with 4sU (Sigma) at a ﬁnal concentration of 100 mM
in cell culture media. Next day, ActD (5mgml) was added to the media and
incubated for 40–45mins. To check the efﬁcacy of ActD treatment, cells were
incubated with and without ActD, and RNA was extracted and assayed level of
c-Myc RNA, with a short half-life, by RT–qPCR. After ActD incubation, cells were
washed two times with PBS and crosslinked with 1% formaldehyde for 10min with
gentle shaking. Crosslinking was stopped by adding glycine to a ﬁnal concentration
of 125mM and incubated for 5min with gentle shacking. Cells were subsequently
washed twice with PBS followed by crosslinking on ice with ultraviolet. Cells were
removed by scraping from the plate and resuspended in cold PBS. Nuclei were
isolated using 1 nuclei isolation buffer (40mM Tris-HCl (pH 7.5),
20mMMgCl2, 4% Triton X-100 and 1.28M sucrose) and washed again with PBS.
The isolated crosslinked nuclei were resuspended in lysis buffer (0.1% SDS, 0.5%
Triton X-100, 20mM Tris-HCl (pH 7.5), 150mM NaCl and 1ml lysis buffer per 10
million of cells) supplemented with RNasein (Promega) and subjected to sonication
(Bioruptor, 20-30 cycles) to obtain chromatin fragments of B1 kb. An amount of
50–60 mg of soluble chromatin was used in each chromatin immunoprecipitation
and incubated with 5 mg of anti-EZH2 (active motif) and anti-H3K27me3 (Merck-
Millipore) antibody. Antibody-bound chromatin was washed according to our
earlier published protocol with buffers and was supplemented with RNasein.
Protein A magnetic beads bound to immunoprecipitated chromatin were
resuspended in 10 volume of elution buffer (100mM NaCl, 10mM Tris
(pH 7.5), 1mM EDTA and 0.5% SDS) containing proteinase K. Proteinase K
treatment was carried out at 55 C for 45min followed by heating at 95 C for
10min to reverse crosslinking. Chromatin-bound RNA was extracted with Trizol
(Life Technologies) and subjected to DNase I (Promega) treatment to remove
traces of DNA. Since the chromatin-bound RNA yield from one single experiment
is suboptimal for high-throughput sequencing, we pooled RNA from 6 to 8 ChRIP
pull-downs, and the sequencing library was made using SOLiD Total RNA-Seq Kit
and sequenced the library using SOLiD platform (Applied Biosystem). SOLiD
Total RNA-Seq Kit allows obtaining strand-speciﬁc RNA sequencing information.
Since library preparation in SOLID protocol involves ligation of RNA adaptors to
the RNA fragments by RNA ligase, no contamination from DNA fragments is
expected. For input, nuclear RNA was isolated from 4sU- and ActD-treated
BT-549 cells, and depleted ribosomal RNA using RiboMinus Eukaryote System v2
(Life Technologies). For ChRIP validation, we followed the same protocol as
described above with or without ActD treatment using antibodies against
H3K27me3, EZH2, H3K4me2 (Merck-Millipore) and nonspeciﬁc Rabbit IgG
(immunoglobulin G; Merck-Millipore).
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